Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06351527
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-08
First Post:
2024-04-02
Brief Title:
Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of ICP-248 in Mature B-cell Malignancies
Sponsor:
InnoCare Pharma Inc
Organization:
InnoCare Pharma Inc
Study Overview
Official Title:
A Phase I Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of ICP-248 in Patients With Mature B-cell Malignancies
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of ICP-248 in Mature B-cell Malignancies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None